Time on allocated treatment (retention time) · people with focal or generalized seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retention [ · people with focal or generalized seizures
Clobazam showed no clear difference in retention at 12 months compared with carbamazepine (low certainty).
1 finding from 1 review
Seizure freedom · people with focal or generalized seizures
Clobazam showed no clear difference in seizure freedom at 4 weeks compared with carbamazepine (low certainty).
2 findings from 1 review
50% responder rate · people with focal or generalized seizures
Clobazam showed no clear difference in 50% responder rate compared with carbamazepine (low certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · people with focal or generalized seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to treatment withdrawal · people with epilepsy
VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation · people with epilepsy
It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with epilepsy
VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review